Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Shares in GSK maintain been in the doldrums since the market started to worry about legal action concerning heartburn treatment Zantac and accusations that it causes cancer.
Investors maintain feared it could be forced to pay out billions in compensation.
AJ Bell’s Russ Mould said: “Slowly, GSK seems to be winning the battle after a Canadian court dismissed a proposed class action, following a similar creep in the US late last year.
“While the legal fight is not over, the latest news gives investors a novel reason to reappraise GSK, along with news that it has successfully sold a chunk of its shares in Haleon at a adjacent-market price. The business was created from assets owned by GSK and Pfizer, and the two drug companies remained shareholders when the demerger happened.
“They both said they would sell down their positions in time, but the ease at which GSK has placed 240 million shares in Haleon would suggest it won’t maintain a predicament selling the remaining 10.3% stake in the business.
“Essentially that is also excellent news for Haleon and the perceived risk to its share price from the significant overhang – there is nothing worse than two considerable shareholders openly saying they don’t want to maintain their shares for long.”
